HomeCompareELEV vs O

ELEV vs O: Dividend Comparison 2026

ELEV yields 547.95% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELEV wins by $125545.51M in total portfolio value
10 years
ELEV
ELEV
● Live price
547.95%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$125545.55M
Annual income
$92,380,482,230.31
Full ELEV calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — ELEV vs O

📍 ELEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELEVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELEV + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELEV pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELEV
Annual income on $10K today (after 15% tax)
$46,575.34/yr
After 10yr DRIP, annual income (after tax)
$78,523,409,895.76/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, ELEV beats the other by $78,523,405,562.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELEV + O for your $10,000?

ELEV: 50%O: 50%
100% O50/50100% ELEV
Portfolio after 10yr
$62772.79M
Annual income
$46,190,243,664.25/yr
Blended yield
73.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ELEV right now

ELEV
Analyst Ratings
3
Buy
8
Hold
1
Sell
Consensus: Hold
Price Target
$9.00
+2365.8% upside vs current
Range: $8.00 — $10.00
Altman Z
-4.8
Piotroski
1/9
O
No analyst data
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELEV buys
0
O buys
0
No recent congressional trades found for ELEV or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELEVO
Forward yield547.95%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$125545.55M$34.2K
Annual income after 10y$92,380,482,230.31$5,098.20
Total dividends collected$122722.76M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ELEV vs O ($10,000, DRIP)

YearELEV PortfolioELEV Income/yrO PortfolioO Income/yrGap
1← crossover$65,495$54,794.52$10,818$607.86+$54.7KELEV
2$405,475$335,396.34$11,786$741.30+$393.7KELEV
3$2,374,450$1,940,591.70$12,944$910.50+$2.36MELEV
4$13,161,259$10,620,596.57$14,343$1,127.28+$13.15MELEV
5$69,099,868$55,017,321.36$16,053$1,408.17+$69.08MELEV
6$343,894,398$269,957,539.26$18,167$1,776.65+$343.88MELEV
7$1,623,590,885$1,255,623,879.22$20,815$2,266.60+$1623.57MELEV
8$7,277,465,834$5,540,223,587.11$24,179$2,927.66+$7277.44MELEV
9$30,995,389,120$23,208,500,677.65$28,521$3,833.95+$30995.36MELEV
10$125,545,548,589$92,380,482,230.31$34,218$5,098.20+$125545.51MELEV

ELEV vs O: Complete Analysis 2026

ELEVStock

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Full ELEV Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ELEV vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELEV vs SCHDELEV vs JEPIELEV vs KOELEV vs MAINELEV vs STAGELEV vs ADCELEV vs NNNELEV vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.